Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24747882 | 0.85 | SMN1; SMN2 (0.36) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL26677728 | 0.84 | DGAT1 (0.36) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL19225976 | 0.81 | RAB9A (0.33) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL29050026 | 0.80 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL25413973 | 0.80 | DGAT1 (0.34) | NPC1DGAT1 | |
| SCHEMBL27154335 | 0.80 | ALDH1A1 (0.32) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL17794927 | 0.79 | NPC1 (0.31) | NPC1DGAT1 | |
| SCHEMBL4427300 | 0.79 | DGAT1 (0.34) | NPC1LMNADGAT1 | |
| SCHEMBL20338885 | 0.79 | ALDH1A1 (0.34) | RAB9ASMN1; SMN2L3MBTL1NPC1KMT2A | |
| SCHEMBL21544284 | 0.79 | NPC1 (0.32) | NPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212638-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3212638-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016066662-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016066662-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| EP-2450358-A1 | Fused, tricyclic sulfonamide inhibitors of gamma secretase | Elan Pharmaceuticals Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2450358-A1 | Fused, tricyclic sulfonamide inhibitors of gamma secretase | Elan Pharmaceuticals Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2038280-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | RECQL, NDUFS5, NDUFS7 | RAB9A 262/4885SMN1; SMN2 2956/4885DUSP3 4428/4885 |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | RAB9A 1268/4885SMN1; SMN2 1394/4885DUSP3 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.